The study is a multi-center, prospective, one-arm, phase II clinical trial. It is tend to
examine the safety and efficacy of combining abraxane(albumin-bound paclitaxel and
bevacizumab to treat patients with recurrent, platinum-resistant primary epithelial ovarian
cancer, fallopian tube cancer or peritoneal carcinoma.
Objective Response Rate
albumin-bound paclitaxe combined with bevacizumab biosimilar
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.